Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 37
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Am J Emerg Med ; 36(5): 829-833, 2018 May.
Artículo en Inglés | MEDLINE | ID: mdl-29056392

RESUMEN

OBJECTIVE: The aim of this randomized cross-over study was to compare one-minute and two-minute continuous chest compressions in terms of chest compression only CPR quality metrics on a mannequin model in the ED. MATERIALS AND METHODS: Thirty-six emergency medicine residents participated in this study. In the 1-minute group, there was no statistically significant difference in the mean compression rate (p=0.83), mean compression depth (p=0.61), good compressions (p=0.31), the percentage of complete release (p=0.07), adequate compression depth (p=0.11) or the percentage of good rate (p=51) over the four-minute time period. Only flow time was statistically significant among the 1-minute intervals (p<0.001). In the 2-minute group, the mean compression depth (p=0.19), good compression (p=0.92), the percentage of complete release (p=0.28), adequate compression depth (p=0.96), and the percentage of good rate (p=0.09) were not statistically significant over time. In this group, the number of compressions (248±31 vs 253±33, p=0.01) and mean compression rates (123±15 vs 126±17, p=0.01) and flow time (p=0.001) were statistically significant along the two-minute intervals. There was no statistically significant difference in the mean number of chest compressions per minute, mean chest compression depth, the percentage of good compressions, complete release, adequate chest compression depth and percentage of good compression between the 1-minute and 2-minute groups. CONCLUSION: There was no statistically significant difference in the quality metrics of chest compressions between 1- and 2-minute chest compression only groups.


Asunto(s)
Reanimación Cardiopulmonar , Auxiliares de Urgencia , Masaje Cardíaco/métodos , Maniquíes , Estudios Cruzados , Humanos , Análisis y Desempeño de Tareas , Factores de Tiempo
2.
Med Princ Pract ; 26(1): 50-56, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-27780164

RESUMEN

OBJECTIVE: To investigate the symptoms of lung cancer in Turkey and to evaluate approaches to alleviate these symptoms. SUBJECTS AND METHODS: This study included 1,245 lung cancer patients from 26 centers in Turkey. Demographic characteristics as well as information regarding the disease and treatments were obtained from medical records and patient interviews. Symptoms were evaluated using the Edmonton Symptom Assessment Scale (ESAS) and were graded on a scale between 0 and 10 points. Data were compared using the χ2, Student t, and Mann-Whitney U tests. Potential predictors of symptoms were analyzed using logistic regression analysis. RESULTS: The most common symptom was tiredness (n = 1,002; 82.1%), followed by dyspnea (n = 845; 69.3%), appetite loss (n = 801; 65.7%), pain (n = 798; 65.4%), drowsiness (n = 742; 60.8%), anxiety (n = 704; 57.7%), depression (n = 623; 51.1%), and nausea (n = 557; 45.5%). Of the 1,245 patients, 590 (48.4%) had difficulty in initiating or maintaining sleep. The symptoms were more severe in stages III and IV. Logistic regression analysis indicated a clear association between demographic characteristics and symptom distress, as well as between symptom distress (except nausea) and well-being. Overall, 804 (65.4%) patients used analgesics, 630 (51.5%) received treatment for dyspnea, 242 (19.8%) used enteral/parenteral nutrition, 132 (10.8%) used appetite stimulants, and 129 (10.6%) used anxiolytics/antidepressants. Of the 799 patients who received analgesics, 173 (21.7%) reported that their symptoms were under control, and also those on other various treatment modalities (dyspnea: 78/627 [12.4%], appetite stimulant: 25/132 [18.9%], and anxiolytics/antidepressants: 25/129 [19.4%]) reported that their symptoms were controlled. CONCLUSION: In this study, the symptoms progressed and became more severe in the advanced stages of lung cancer, and palliative treatment was insufficient in most of the patients in Turkey.


Asunto(s)
Neoplasias Pulmonares/complicaciones , Neoplasias Pulmonares/psicología , Neoplasias de Células Escamosas , Cuidados Paliativos , Adulto , Anciano , Analgésicos/uso terapéutico , Comorbilidad , Disnea/complicaciones , Disnea/epidemiología , Fatiga/complicaciones , Fatiga/epidemiología , Femenino , Humanos , Entrevistas como Asunto , Modelos Logísticos , Neoplasias Pulmonares/terapia , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Dolor/complicaciones , Dolor/epidemiología , Calidad de Vida , Turquía/epidemiología
3.
Int J Clin Pract ; 66(2): 152-7, 2012 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22188416

RESUMEN

AIMS: Few studies exist on influence of long-term oxygen treatment (LTOT) on survival of chronic obstructive pulmonary disease (COPD) patients. This study was designed to determine whether LTOT improves survival or not in severely hypoxaemic COPD patients. MATERIALS: COPD patients prescribed oxygen concentrator were consecutively included. Patients' baseline characteristics were noted. During follow-up, patients were divided into three groups according to LTOT utilisation: (i) non-utilisers, (ii) intermittent utilisers (< 15 h/day) and (iii) true utilisers (≥ 15 h/day). Patients' status (live or death) and, if died, the date of death were checked throughout the study. The factors which might influence mortality during 5-year period were analysed. RESULTS: Two-hundred and twenty-eight patients completed the study. Of these patients, 55 were in Group 1, 112 were in Group 2 and 61 were in Group 3. Regarding the initial characteristics, there was not any significant difference between groups. Mean follow-up for whole group was 27.8 ± 18.5 months. Median survivals were similar between groups (19.5 ± 5.6, 32.5 ± 4.1 and 30.0 ± 5.7 months respectively) (p > 0.05). Compared with Group 1, survival was improved in Group 2 (p < 0.05) and there was a positive trend for Group 3 during first 2-year period. However, this improvement disappeared during further follow-up. Analysis of multiple factors which might influence mortality during 5-year period did not yield statistically significant parameter. DISCUSSION AND CONCLUSION: We found that, regarding survival, any kind of LTOT proved to be beneficial over no LTOT only in the first 2 years of follow-up, and that there was not any difference between intermittent and true LTOT utilisation.


Asunto(s)
Terapia por Inhalación de Oxígeno , Oxígeno/uso terapéutico , Enfermedad Pulmonar Obstructiva Crónica/terapia , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Estudios de Seguimiento , Volumen Espiratorio Forzado/fisiología , Humanos , Estimación de Kaplan-Meier , Cuidados a Largo Plazo , Masculino , Persona de Mediana Edad , Enfermedad Pulmonar Obstructiva Crónica/mortalidad , Capacidad Vital/fisiología
4.
Neurochirurgie ; 68(1): 106-112, 2022 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-33652067

RESUMEN

INTRODUCTION: Pituitary carcinomas are rare, with only a few case reports to date. We present a null cell type non-functioning pituitary carcinoma (NFPC) with intracranial metastases and a review of the literature. CASE REPORT: A 56-year-old male with a history of an aggressive pituitary adenoma was admitted. Initial MRI highlighted a large intracranial mass with leptomeningeal involvement, simulating meningioma. Based on his previous pathology report of the sellar mass, a diagnosis of null cell type non-functioning pituitary carcinoma has been made. CONCLUSIONS: An aggressive recurrent pituitary tumor with suprasellar and/or cavernous sinus invasion is the main characteristics of the NFPC. Single or multiple enhancing dural-based mass(es) mimicking meningioma is the most common MRI finding. The proof of malignancy is the same histopathological features of the recurrent aggressive pituitary tumor in the metastases. The histology alone is not distinctive in terms of malignancy. Most patients require a combined surgery, radiotherapy and chemotherapy.


Asunto(s)
Adenoma , Neoplasias Meníngeas , Meningioma , Neoplasias Hipofisarias , Adenoma/diagnóstico por imagen , Adenoma/cirugía , Humanos , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/diagnóstico , Neoplasias Hipofisarias/diagnóstico por imagen , Neoplasias Hipofisarias/cirugía
5.
J BUON ; 15(2): 274-80, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20658721

RESUMEN

PURPOSE: To evaluate the efficacy of gamma knife radiosurgery (GKRS) for the treatment of brain metastases from non small cell lung cancer (NSCLC) and find out the prognostic factors for overall survival. METHODS: Between February 1997 and August 2003 100 patients underwent treatment for 184 brain metastases from NSCLC, either for recurrence (n=49) or with a new diagnosis (n=51). Median age was 55 years and 77 patients were male. Seventy-eight of the patients received whole brain radiotherapy (WBRT) prior to or after GKRS and 26 patients had surgical removal of the metastasis. Imaging and clinical status were monitored every 3 months following treatment. Kaplan-Meier survival curves, Cox proportional hazards regression for risk factor analysis were used. RESULTS: The median follow up after the procedure was 8 months and after the diagnosis 11 months. The median overall survival for all patients was 9 months from the date of GKRS and 14 months from the diagnosis of brain metastasis. Local tumor control was achieved in 95% of the lesions. In multivariate analysis, adenocarcinoma histology, Karnofsky performance status (KPS) score > 80, 1-3 metastases and tumor diameter <2 cm were related to longer survival. Addition of WBRT did not have any effect on overall survival. CONCLUSION: Gamma knife surgery appears to be effective in treating patients with brain metastases from NSCLC, either alone or with WBRT in selected groups of patients.


Asunto(s)
Neoplasias Encefálicas/secundario , Neoplasias Encefálicas/cirugía , Carcinoma de Pulmón de Células no Pequeñas/cirugía , Radiocirugia , Actividades Cotidianas , Adulto , Anciano de 80 o más Años , Neoplasias Encefálicas/mortalidad , Carcinoma de Pulmón de Células no Pequeñas/mortalidad , Carcinoma de Pulmón de Células no Pequeñas/patología , Femenino , Humanos , Estimación de Kaplan-Meier , Estado de Ejecución de Karnofsky , Masculino , Persona de Mediana Edad , Pronóstico , Calidad de Vida , Estudios Retrospectivos , Tasa de Supervivencia , Factores de Tiempo
6.
Acta Neurochir (Wien) ; 150(7): 625-35; discussion 635-6, 2008 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-18509587

RESUMEN

BACKGROUND: Anterior clinoidal meningiomas are considered different from meningiomas of the medial sphenoid wing, but there is still some confusion about identification. The current classification scheme only considers tumour origin and invasion pattern around the clinoid process as indicators of resectability. However, the size of the tumour has important effects on surgical outcome. The purpose of this study was to analyze our clinical experience with anterior clinoidal meningiomas and refine the current classification scheme. METHOD: Forty-three consecutive cases of anterior clinoidal meningioma were retrospectively analyzed. All were surgically treated at the Marmara University Department of Neurosurgery, the Marmara University Institute for Neurological Sciences, and the Department of Neurosurgery at Acibadem Hospital between 1987 and 2006. A pterional approach was used in all cases. FINDINGS: The mean tumour volume was 34.2 +/- 46.6 cc. Sixteen (37.2%) of the tumours were giant (largest diameter >4 cm). Total surgical removal was achieved in 39 cases (90.7%) and subtotal removal in 4 cases (9.3%). Eight patients (18.6%) developed early postoperative complications. The median and range of follow-up time was 39, R = 99 (3, 102) months. Four (9.3%) of the 43 tumours recurred during follow-up and were treated with radiosurgery. CONCLUSION: Anterior clinoidal meningioma is a separate disease entity from other meningiomas of the medial third of the sphenoid wing. Relatively good outcomes can be stated in this specific subgroup if growth criteria competable with true diagnosis are fulfilled. Size should be incorporated into any classification scheme for determining clinical and surgical risk. The standard pterional approach is sufficient for removing anterior clinoidal meningiomas.


Asunto(s)
Neoplasias Meníngeas/clasificación , Neoplasias Meníngeas/cirugía , Meningioma/clasificación , Meningioma/cirugía , Procedimientos Neuroquirúrgicos , Adulto , Anciano , Femenino , Estudios de Seguimiento , Humanos , Estimación de Kaplan-Meier , Imagen por Resonancia Magnética , Masculino , Neoplasias Meníngeas/complicaciones , Neoplasias Meníngeas/diagnóstico , Meningioma/complicaciones , Meningioma/diagnóstico , Microcirugia , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Complicaciones Posoperatorias , Estudios Retrospectivos , Hueso Esfenoides/cirugía , Tomografía Computarizada por Rayos X
7.
Acta Neurochir (Wien) ; 149(11): 1133-7; discussion 1137, 2007 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-17728994

RESUMEN

BACKGROUND: Trigeminal nerve schwannomas account for 0.07%-0.28% of all intracranial tumours. Advances in skull base surgery have led to more aggressive resection of these tumours, but surgery may associated with development of new neurological deficits. METHODS: In this report, we analyse the long-term results 15 patients with newly diagnosed or residual/recurrent trigeminal schwannoma who underwent gamma-knife treatment. FINDINGS: During a mean 61 months of follow-up, MRI revealed reduction of tumour size in 13 and no size change in 2 patients. The tumour growth control rate was 100% and only 1 patient had transient facial numbness and diplopia. CONCLUSIONS: For patients with small to moderate size trigeminal schwannomas, gamma-knife radiosurgery is associated with good tumour control and a minimal risk of adverse radiation effects.


Asunto(s)
Neoplasias de los Nervios Craneales/cirugía , Recurrencia Local de Neoplasia/cirugía , Neoplasia Residual/cirugía , Neurilemoma/cirugía , Radiocirugia , Enfermedades del Nervio Trigémino/cirugía , Adulto , Anciano , Neoplasias de los Nervios Craneales/diagnóstico , Femenino , Estudios de Seguimiento , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia/diagnóstico , Neoplasia Residual/diagnóstico , Neurilemoma/diagnóstico , Examen Neurológico , Enfermedades del Nervio Trigémino/diagnóstico
9.
Cancer Res ; 60(18): 5143-50, 2000 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-11016641

RESUMEN

Glioblastoma multiforme is the most common primary human brain tumor, and it is, for all practical purposes, incurable in adult patients. The high mortality rates reflect the fact that glioblastomas are resistant to adjuvant therapies (radiation and chemicals), the mode of action of which is cytotoxic. We show here that an p.o.-active small molecule kinase inhibitor of the 2-phenylaminopyrimidine class may have therapeutic potential for glioblastomas. STI571 inhibits the growth of U343 and U87 human glioblastoma cells that have been injected into the brains of nude mice, but it does not inhibit intracranial growth of ras-transformed cells. Studies on a broad panel of genetically validated human and animal cell lines show that STI571 acts by disruption of the ligand:receptor autocrine loops for platelet-derived growth factor that are a pervasive feature of malignant astrocytoma. The cellular response of glioblastoma cells to STI571 does not appear to involve an apoptotic mechanism.


Asunto(s)
Antineoplásicos/farmacología , Neoplasias Encefálicas/tratamiento farmacológico , Inhibidores Enzimáticos/farmacología , Glioblastoma/tratamiento farmacológico , Piperazinas , Factor de Crecimiento Derivado de Plaquetas/antagonistas & inhibidores , Pirimidinas/farmacología , Células 3T3 , Animales , Apoptosis/efectos de los fármacos , Benzamidas , Neoplasias Encefálicas/patología , División Celular/efectos de los fármacos , División Celular/fisiología , Transformación Celular Viral , Relación Dosis-Respuesta a Droga , Glioblastoma/patología , Inhibidores de Crecimiento/farmacología , Células HeLa , Humanos , Mesilato de Imatinib , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Trasplante de Neoplasias , Factor de Crecimiento Derivado de Plaquetas/fisiología , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Receptores del Factor de Crecimiento Derivado de Plaquetas/antagonistas & inhibidores , Receptores del Factor de Crecimiento Derivado de Plaquetas/biosíntesis , Receptores del Factor de Crecimiento Derivado de Plaquetas/fisiología , Células Tumorales Cultivadas
11.
Neurosurgery ; 46(5): 1179-91; discussion 1191-2, 2000 May.
Artículo en Inglés | MEDLINE | ID: mdl-10807251

RESUMEN

OBJECTIVE: The goal of this study was to describe the expression of matrix proteins and angiogenic factors in cerebrovascular malformations. METHODS: Forty-six cerebrovascular malformations were immunohistochemically investigated with a battery of staining for five structural proteins (collagen IV, collagen III, smooth muscle actin, fibronectin, and laminin), and three angiogenic factors (vascular endothelial growth factor [VEGF], basic fibroblast growth factor [bFGF], and transforming growth factor alpha [TGFalpha]). The lesions consisted of 34 arteriovenous malformations (AVMs), 10 cavernous malformations (CMs), and 2 venous angiomas. Expression intensity for each histological layer in the abnormal vessel wall was graded and compared. RESULTS: AVM endothelia and subendothelia expressed more laminin and collagen IV than the same layers of CMs. Conversely, CMs expressed more fibronectin than AVMs. CM endothelia exhibited more prominent staining for smooth muscle actin than AVM endothelia. AVMs and CMs expressed VEGF in the endothelium and subendothelium, and TGFalpha in endothelial and perivascular layers. However, unlike AVMs, CMs expressed bFGF in the endothelium as well. The brain tissue intermingled within AVMs also expressed growth factors. Modified glial cells in the brain tissue adjacent to CMs expressed bFGF and TGFalpha, but not VEGF. Venous angiomas did not express the studied growth factors and mainly consisted of structural proteins of angiogenically mature tissue. CONCLUSION: Expression characteristics of structural proteins reveal that AVMs and CMs have different immunohistological properties. This study provides strong confirmation of previous findings of VEGF and bFGF immunoexpression in AVMs and CMs. It adds new information on TGFalpha expression in these malformations and on expression of the angiogenic factors in venous angiomas.


Asunto(s)
Inductores de la Angiogénesis/análisis , Neoplasias Encefálicas/patología , Proteínas de la Matriz Extracelular/análisis , Sustancias de Crecimiento/análisis , Hemangioma Cavernoso/patología , Hemangioma/patología , Malformaciones Arteriovenosas Intracraneales/patología , Actinas/análisis , Adolescente , Adulto , Niño , Colágeno/análisis , Factores de Crecimiento Endotelial/análisis , Endotelio Vascular/patología , Femenino , Factor 2 de Crecimiento de Fibroblastos/análisis , Fibronectinas/análisis , Humanos , Laminina/análisis , Linfocinas/análisis , Masculino , Músculo Liso Vascular/patología , Factor de Crecimiento Transformador alfa/análisis , Factor A de Crecimiento Endotelial Vascular , Factores de Crecimiento Endotelial Vascular
12.
Pediatr Neurol ; 15(1): 53-6, 1996 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-8858701

RESUMEN

Two cases of neonatal intracerebral hemorrhage secondary to rupture of arteriovenous malformation are reported and the pertinent literature is reviewed. Despite the limited number of cases, review of the literature and our results demonstrate that the outcome of surgical removal of an arteriovenous malformation in the neonatal period is not as poor as was previously believed.


Asunto(s)
Aneurisma Roto/etiología , Hemorragia Cerebral/etiología , Malformaciones Arteriovenosas Intracraneales/complicaciones , Edema Encefálico/etiología , Craneotomía , Epilepsia Tónico-Clónica/etiología , Femenino , Humanos , Hidrocefalia/etiología , Hidrocefalia/cirugía , Recién Nacido , Aneurisma Intracraneal/etiología , Aneurisma Intracraneal/cirugía , Malformaciones Arteriovenosas Intracraneales/cirugía , Masculino , Rotura Espontánea , Derivación Ventriculoperitoneal
13.
Yonsei Med J ; 42(3): 299-303, 2001 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11456395

RESUMEN

Monitoring fetal growth and assessing its predictors have important place in antenatal care management. Accurate prediction of gestational age (GA) and birth weight (BW) is clinically important. Standard growth curve chosen should be evaluated to see if it satisfies the criteria for a valid assesment. In this paper, for the purpose of contributing to develop national standards and to evaluate Hadlock's standard data pertaining to 1411 fetuses were examined. Of 1411 normally growing fetuses, one measurement for AC, BPD and FL was taken by ultrasound. GA was assessed via menstrual history which is also confirmed by ultrasonography. Several variables, AC, BPD, FL, FL/AC, BPD/FL and dependent variables (GA & BW) were modelled mathematically. Percentile values, correlation coefficients were calculated and well functioning regression equations were produced for the fetal growth evaluation. Simple correlation model re-confirmed that AC, BPD and FL were well predictors of GA. Via modelling by multivariate regression analysis (adj. R2=937), GA=4.945 (95% CI: 4.661- 5.654) + .606 AC + .105 BPD + .286 FL can be estimated. It couldn't be possible establishing an appropriate equation for prediction of BW with current data. Our study is intended to draw an attention on requirement of national standards although Hadlock's standard growth curve may evaluate fetal development accurately. Forming comprehensive cohort group is under our consideration. The equation we developed (shown in the results), might be a working contribution.


Asunto(s)
Desarrollo Embrionario y Fetal , Edad Gestacional , Ultrasonografía Prenatal , Estudios Transversales , Femenino , Humanos , Embarazo , Análisis de Regresión
14.
Tumori ; 87(1): 60-3, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11669561

RESUMEN

Neurofibromatosis type I (NF I) is the most common hereditary syndrome predisposing to neoplasia. We report the third case in the literature, documenting the combination of gliosarcoma with NF I. The patient's son was known at our center because of a history of pleomorphic xanthoastrocytoma (PXA) with NF I. A 48-year-old man who had a number of café-au-lait spots with neurofibroma since birth presented with severe headache. Neuroradiological studies revealed a cystic tumor of the right temporal lobe of high grade nature. Surgical excision was performed and the tumor was found to be located on the surface of the temporoparietal area with cystic formation and vascular and infiltrative features. Postoperative MRI Key words: gliosarcoma, neurofibromatosis I, temporal lobe. showed no detectable contrast enhancing tissue. Immunohistochemical examination evidenced the characteristics of typical gliosarcoma. The patient received radiation therapy but five months following surgery recurrence of the tumor was diagnosed. Reoperation was performed and histopathological studies confirmed the diagnosis of gliosarcoma. We believe that the neurofibromatosis was inherited by the son with PXA from the father with gliosarcoma. The rarity of the combined occurrence of gliosarcoma and NF I, in addition to this uncommon family history, makes this case remarkable. Our findings suggest that NF I is a multifaceted disease associated with benign as well as malignant astrocytic tumors.


Asunto(s)
Neoplasias Encefálicas , Gliosarcoma , Neoplasias Primarias Múltiples , Neurofibromatosis 1 , Lóbulo Temporal , Neoplasias Encefálicas/diagnóstico , Neoplasias Encefálicas/cirugía , Gliosarcoma/diagnóstico , Gliosarcoma/cirugía , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Neoplasias Primarias Múltiples/diagnóstico , Neoplasias Primarias Múltiples/cirugía , Lóbulo Temporal/patología , Lóbulo Temporal/cirugía
15.
Fitoterapia ; 72(1): 1-4, 2001 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11163933

RESUMEN

The known ent-kaurene diterpenes 1-9 and a new ent-labdane, ent-6beta,8alpha-dihydroxylabda-13(16),14-diene (10), were isolated from the whole plant of Sideritis argyrea. Their structures were elucidated based on one- and two-dimensional NMR techniques and HRMS.


Asunto(s)
Diterpenos/química , Lamiaceae , Plantas Medicinales/química , Diterpenos/aislamiento & purificación , Humanos , Espectroscopía de Resonancia Magnética , Espectrometría de Masas , Extractos Vegetales/química , Extractos Vegetales/aislamiento & purificación , Espectrofotometría Infrarroja
16.
Eur Rev Med Pharmacol Sci ; 18(18): 2615-20, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-25317794

RESUMEN

OBJECTIVE: The objective of this study is to evaluate the auditory functions in chronic asthma patients with the use of pure tone high frequency audiometry. PATIENTS AND METHODS: Twenty-two healthy controls and 42 adult patients were included as a prospective, randomized, and controlled study. Pulmonary function tests and blood gas studies were completed on all subjects. Asthma patients have divided into two groups [Group A: Arterial oxygen tension (PaO2) > 75 mmHg, Group B: PaO2 ≤ 75 mmHg, Group C: Control group). Acoustic assessments of patients were performed in 250-20,000 Hz by using pure-tone audiometry (PTA) and tympanometry. RESULTS: The mean value of air and bone conduction hearing threshold levels were in normal range for all groups. All patients had normal peripheral hearing all threshold levels across 250 Hz to 3000 Hz in the both ears. Significant differences were observed between the chronic asthma patients and control group for the extended high frequencies (10,000-20,000 Hz). Group B had statistically more significant increased hearing threshold levels than Group A in frequencies higher than 10,000 Hz. There were no statistical differences between the hearing threshold levels and FEV1, FVC, FEV1/FVC and tympanogram results in the groups. CONCLUSIONS: This is the first study of evaluating the auditory functions in asthma patients. Sensorineural hearing loss in high frequencies (10,000 Hz-20,000 Hz) is common in chronic asthma and is probably present more often than were formerly thought.


Asunto(s)
Asma/fisiopatología , Audiometría de Tonos Puros/métodos , Pérdida Auditiva Sensorineural/diagnóstico , Pruebas de Impedancia Acústica , Adulto , Umbral Auditivo , Conducción Ósea , Estudios de Casos y Controles , Femenino , Pérdida Auditiva Sensorineural/fisiopatología , Pruebas Auditivas/métodos , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Adulto Joven
17.
Transplant Proc ; 46(1): 33-9, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24507022

RESUMEN

BACKGROUND: To determine effects on calcium and sodium channels of Ca(2+) and Na(+) channel blockers in the present study, expression levels of TRPM1, TRPM2, TRPM3, TRPM4, TRPM5, TRPM6, TRPM7, TRPM8, and NaV1.9 genes were evaluated in kidney tissues after induced ischemia-reperfusion. MATERIAL AND METHODS: Forty albino Wistar male rats were equally divided into 4 groups as follows: group I: control group (n = 10), group II: ischemia group (60 minutes of ischemia + 48 hours of reperfusion; n = 10), group III: ischemia (60 minutes of ischemia + 48 hours of reperfusion) + calcium channel blocker (n = 8), group IV: ischemia (60 minutes of ischemia + 48 hours of reperfusion) + sodium channel blocker (n = 8). RESULTS: When compared to ischemia group expression levels of TRPM2, TRPM4, TRPM6, and NaV1.9 in Ca(2+) and Na(+) channel blocker groups were increased, whereas that of TRPM7 was decreased. However, expression levels of TRPM1, TRPM3, TRPM5, and TRPM8 were not determined in kidney tissue. Histologically, the Ca(2+) channel blocker verapamil and the Na(+) channel blocker lidocaine inhibited the cell death in kidney tissue compared to control. CONCLUSION: Our study suggested that verapamil and lidocaine significantly reduce the degree of ischemia-reperfusion injury due to effects to TRPM and Nav1.9 genes.


Asunto(s)
Bloqueadores de los Canales de Calcio/administración & dosificación , Regulación de la Expresión Génica , Enfermedades Renales/tratamiento farmacológico , Enfermedades Renales/patología , Riñón/patología , Lidocaína/administración & dosificación , Canal de Sodio Activado por Voltaje NAV1.9/metabolismo , Daño por Reperfusión/tratamiento farmacológico , Canales Catiónicos TRPM/metabolismo , Verapamilo/administración & dosificación , Bloqueadores del Canal de Sodio Activado por Voltaje/administración & dosificación , Animales , Canales de Calcio/metabolismo , Modelos Animales de Enfermedad , Masculino , Ratas , Ratas Wistar
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA